A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity. | Mol Cell Biol;12(2): 631-7, 1992 Feb. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity.

Tanaka, K; Wood, D R; Lin, B K; Khalil, M; Tamanoi, F; Cannon, J F.

Affiliation

Tanaka K; Department of Biochemistry and Molecular Biology, University of Chicago, Illinois 60637.

Mol Cell Biol ; 12(2): 631-7, 1992 Feb.

Article in En | MEDLINE | ID: mdl-1732735

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Saccharomyces cerevisiae / Fungal Proteins / Proto-Oncogene Proteins p21(ras) / Genes, ras / GTPase-Activating Proteins / Saccharomyces cerevisiae Proteins Type of study: Diagnostic_studies Language: En Journal: Mol Cell Biol Year: 1992 Document type: Article Country of publication: Estados Unidos

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Saccharomyces cerevisiae / Fungal Proteins / Proto-Oncogene Proteins p21(ras) / Genes, ras / GTPase-Activating Proteins / Saccharomyces cerevisiae Proteins Type of study: Diagnostic_studies Language: En Journal: Mol Cell Biol Year: 1992 Document type: Article Country of publication: Estados Unidos